Background: Theserum erythropoietin level increases markedly during chemotherapy for leukemia. A number of hypotheses have been built for the mechanism, none of them satisfactory. Difficulty in evaluating bone marrow activity hampers the elucidation. Therefore, we focused on patients who had non-hematological cancer and no evidence of bone marrow suppression. Methods: Twelve patients, who had lung cancer (fourwith small cellcancer and eight with non-small cell cancer) and who had not undergone any chemotherapy, were studied. During chemotherapy, we measured serum erythropoietin, serum iron, unsaturated iron binding capacity and hemoglobin concentration in these patients. Results: Theserum erythropoietin level before chemotherapy (10.8 ± 7.4mU/ml) waswithin the normal range butthepeakvalues afterthe first treatment (73.4 ± 90.4mU/ml) increased in all patients. In the patients with small cell cancer, a transient but marked increase in erythropoietin value (204.6 ± 167.3 mU/ml) was observed after each session of chemotherapy while hemoglobin concentration decreased gradually. Throughout treatments, elevation of the serum iron concentration and concomitant reduction of unsaturated iron binding capacity were observed after each session of chemotherapy. They regained their original values whilst the serum erythropoietin level decreased after each chemotherapy session was completed. Conclusions: It is suggested that the suppression of erythroid marrow by chemotherapeutic agents causes the changes in serum erythropoietin level during chemotherapy in patients with lung cancer.
INTRODUCTION
It has been reported that the serum erythropoietin (Epo) level increases markedly during chemotherapy for leukemia or during the conditioning process before bone marrow transplantation (1) (2) (3) (4) . A number of hypotheses for the mechanism of the increase have been proposed, but none so far is satisfactory. Elucidating the mechanism seems to be hampered by difficulty in evaluating bone marrow activity, especially in hematopoietic disorders.
In this paper, we focused on patients who had non-hematological cancer and no evidence of bone marrow suppression. We measured serum Epo, serum iron, unsaturated iron binding capacity (UIBC) and Hb concentration during chemotherapy and analyzed the interrelationship between them in connection with each treatment.
MATERIALS AND METHODS

PATIENTS
Twelve lung cancer patients, who had not undergone any chemotherapy, were studied. They were five females and seven males with a mean age of 62.2 years. Histologically, four patients had small-cell cancer and the rest had non-small-cell cancer. No patient had either hypoxemia (the lowest partial pressure of oxygen was 72 mmHg) or active infection. Table I . shows the profile ofthe patients and the chemotherapy they received.
As a control group for comparing the relationship between Hb level and Epo level, 20 patients with iron deficiency anemia were also studied.
Bone marrow biopsy from the iliac crest was performed in all patients with small cell cancer for assessing the stage of the disease.
METHODS OF MEASUREMENT
Serum Epo was measured with a one-step sandwich enzyme immunoassay (Immunoelite EPO, Toyobo Co., Ltd., Osaka, Japan) (5) using an ELISA analyzer (Behring ELISA Processor II, Behring Werke A.G., Marburg, Germany). The normal range of serum Epo was 4.5-21.3 mU/ml. Serum iron and UIBC were measured with a chelating agent 2-nitro-S-(N-propyl-N-sulfopropylamine) phenol (Quick Auto Neo Fe and Quick Auto Neo UIBC, Shino-Test Co., Tokyo, Japan) with appropriate pretreatments of samples: reduction with ascorbic acid in the former assay and saturation with bivalent iron in the latter. An automatic analyzer (Hitachi autoanalyzer 736-60, Hitachi Ltd., Tokyo, Japan) was used for the assays. The normal range of serum iron and UIBC were 80-170~g/dl and 110-325 ug/dl respectively.
An automatic blood cell counter (Coulter STKS: Coulter Co., Miami, USA) was used for Hb concentration measurement. The normal range was 12-18 g/dl.
Blood samples were collected from the patients after they had fasted overnight.
STATISTICAL ANALYSIS
Data were expressed as mean ± SD. We used Student's r-test to analyze the data statistically. Since serum Epo values were found to follow a logarithmic distribution, we normalized them before analysis. Table 2 shows levels of serum Epo, serum iron, UIBC and Hb before and after chemotherapy.
RESULTS
CHANGES IN LEVELS OF SERUM Ero, SERUM IRON, UIBC AND HB AFTER CHEMOTHERAPY
Before chemotherapy, the serum Epo level in all except one patient was withinthe normalrange (10.8± 7.4 mU/ml).The mean of the peak values after the first treatmentwas 73.4 ± 90.4 mU/ml, which was higher than that before therapy (P < 0.0001).The mean of the Epo values in three patients who had small-cell cancer and underwent 13 courses of chemotherapy was 45.8 ± 57.4 mU/ml before treatment and 204.6 ± 167.3 mU/ml after treatment (P < 0.0001).The averageperiodat whichEpo valuesreached their peaks after the initiation of each chemotherapy was 9.1 days.
Before and after subsequent treatments, the serum iron concentrations and UIBC were 61.5 ± 31.4~g/dl versus 222.5 ± 46.0 ug/dl and 187.4 ± 58.6 ug/dl versus 17.9 ± 24.7 ug/dl respectively (P < 0.0001 for both). Figure 2 depicts the correlation between Hb level and Epo level in all patients before and after treatments, and in patients with iron Figure 1depicts serialchanges in levels of serum Epo, serum iron, deficiency anemia for comparison (log y = -0.621x + 9.91, urnc and Hb in a patient with small cell cancer (Case 2) during P < 0.0001). Inthis Fig. , Epo values in lung cancer patients are the chemotherapy. The Hb concentration, which was normal before maximum values after each session of chemotherapy. The Epo treatment, gradually decreased during treatments. The serum Epo values during treatments were higher than those expected from level transiently increased soon after each treatment. Although the Hb concentration in iran deficiency anemia. the increase was small at the first chemotherapy, the peak value in each treatment increased with subsequent treatments.
SERIAL CHANGES IN LEVELS OF SERUM Ero, SERUM IRON, CORRELATION BETWEEN HB LEVEL AND SERUM EpO LEVEL UIBC AND HB DURING CHEMOTHERAPY -A REPRESENTATIVE CASE
BONE MARROW BIOPSY The serum iron concentration increased with the Epa level, while UIBC decreased. When the Epo value went down, levels of There were no abnormal findings in the bone marrow of any of serum iron and UIBC returned to their initial values.
the patients with small-cell cancer. Table 1 . Each arrow representsa 400 ml blood transfusion.
DISCUSSION
This study in lung cancer patients found that an increase in serum Epo level occurred after the first session of chemotherapy, although the increase was small. Furthermore, in some patients with small-cell cancer, a transient but marked increase occurred after each treatment while the concentration of Hb decreased gradually.
To avoid difficulty in evaluating bone marrow activity, we focused on patients who had lung cancer and who had no evidence of bone marrow suppression. In this study, four patients with small-cell cancer were shown through biopsy to have normal bone marrow, although we could not assess the rest. Moreover, in all patients except one (mild anemia in case 11), the concentration of Hb was within or near the normal range, and the partial pressure of oxygen was more than 72 mmHg at the start of the first session of chemotherapy. It seemed that our patients did not have such anemia or hypoxemia as might have induced Epo production, as their Epo values before the first treatment were within the normal range. This suggests that the serum Epo increase after the first session of chemotherapy in these patients was the result of erythroid marrow suppression.
We have several reports (1-3) at hand as well as ours (4) that address the increase in Epo level during chemotherapy in leukemias, all describing abnormal bone marrow. At this point, we see a difference in bone marrow findings between these patients and our own.
Regarding the degree of Epo increase after the first treatment, we found that the increase in our patients was not as marked as that in leukemias (4) . We speculate that the difference might result from the difference in erythroid marrow activity.
A transient but marked increase in the Epo value was observed in some patients (Cases 1,2,4 and 10) as they underwent each session of chemotherapy subsequent to the first. Similar findings were reported by previous investigators (6,7). However, Miller et al. pointed out that the Epo response to anemia was significantly lower in patients who were receiving chemotherapy than in either patients who received no treatment, or patients who had not received therapy for more than 6 weeks (8) . Comparing the mean concentrations of Hb before chemotherapy in the literature, we found the similar levels in the above two reports (6,7) and ours (around 12.5 g/dl) but a lower level in Miller's report (10.3 g/dl) (8). Miller et al. focused on the cancer patients who already had anemia. Inadequate Epo production was suggested as a contributing factor to this. Therefore, the blunted Epo response to anemia in their patients might also be ascribed to the inadequate Epo production. We think the marked increase of Epo indicates the progressive suppression of erythroid marrow by chemotherapy. Jacobs et al. reported that the serum Epo level in was reversed when the Epo value leveled down after each chemotherapy was completed. We observed this phenomenon in all patients studied. Moreover, we had reported the same phenomenon in chemotherapy for patients with polycythemia vera (11). The phenomenon might be a result of the reduction in iron consumption following a decrease in the number of erythroblasts in chemotherapy. Although blockage of the reticuloendothelial system by chemotherapeutic agents is another possible explanation, we do not think that the serum iron increase could be ascribed to iron excess because the increase was transient, and our patients had no evidence of liver injury which might have caused iron release from the liver.
In summary, we have shown that an increase in serum Epo level occurs after the first session of chemotherapy in patients with lung cancer. Since we focused on subjects who had no prior evidence of bone marrow suppression, it is suggested that the increase results from the suppression of erythroid marrow by chemotherapy. myelodysplastic syndrome was the highest when erythroblast hypoplasia was present in the bone marrow, suggesting that the degree of erythroblast activity in the bone marrow, as well as the degree of anemia, could be a regulating factor of serum Epo level (9) . Moreover, although experimental, it was shown that the half-life of serum Epo was retarded in rats with radiation-suppressed bone marrow as opposed to normal ones (10) .
On the other hand, an interesting finding was that in each treatment, a transient increase in the concentration of serum iron and concomitant decrease in UIBC were observed when a transient but marked increase in Epo level occurred. The change Figure 2 . Relationship between the Hb concentration and serum Epa before and during chemotherapy. Open circles, before chemotherapy; solid circles, during the first treatment; solid squares, during the second and subsequent treatments. The gray area is the normal range of serum Epa.
